Clearance for Proof-of-Concept Phase I human trial in oncology received from Israeli Ministry of Health
The results demonstrate the efficacy of Biomica’s live bacterial consortia, BMC333, for the treatment of IBD
Biomica expects to initiate first-in-human, proof-of-concept study later this year
Today announced that Dr. Elran Haber, Chief Executive Officer of Biomica, will present at the Jefferies Microbiome-Based Therapeutics Summit being held on Thursday, April 22, 2021.
Biomica’s live biotherapeutic drug candidate, BMC128, significantly increased anti-tumor activity in combination with Immune Checkpoint Inhibitors in Melanoma. First-in-human, proof of concept study expected later this year
